In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

Controller medications, also known as daily maintenance medications, are a critical tool for managing asthma — reducing daily ...

Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

There’s no better time to be alive, only if we can learn to thrive amidst constant change and disruption” muses health tech ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...

Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.

ASHG welcomed eight 2024–2026 Human Genetics Scholars who are recognized for their accomplishments and commitment to fostering DEI in human genetics and genomics.